Spray to prevent flu FDA approves AstraZeneca's FluMist vaccine

The U.S. FDA approved AstraZeneca's (AZN.US) FluMist, a nasal spray vaccine, for the prevention of influenza disease caused by A and B influenza viruses in people aged 2 to 49. FluMist is the first influenza vaccine available for eligible patients to self-administer or for caregivers to administer.